Gemcitabine HCl Market Experiences Healthy 6.7% Growth Through 2027
Consistent R&D in the healthcare industry is offering material benefits to the society, thereby, substantially improving the average life expectancies and quality of living.
In addition, the healthcare vertical is accelerating its shift towards a value-based structure that includes rethinking patient care delivery, cost-effectiveness, and customizing patient experience.
As per the World Health Organization (WHO), cancer causes about 16% of mortalities all over the world, with around 70% of them occurring in low- and middle-income economies (LME).
In the US alone, nearly 90, 000 cancer cases are estimated to be diagnosed in 2020.
This demanding situation is compelling governments all over the world to invest in healthcare system at scale, particularly in oncology research, in a bid to reach a larger patient base.
Against this backdrop, the global gemcitabine HCl market will grow at a healthy CAGR of 6.7% over 2020-2027.
Among the end users, hospitals are expected to capture higher revenue share, while upsurge in oncology research projects in cancer centers are offering new revenue streams.
Preference for Generic Drugs to Remain Intact
Both, generic and branded drugs exhibit identical efficiency in cancer treatment and contain the same active ingredient.
However, generic drugs emerge as clear winner in terms of cost, as such, and this is garnering huge investments from stakeholders.
Hospitals and cancer research centers are encountering supply shortage of generic injectable drugs in key therapeutic areas such as oncology, and cardiology, a potential opportunity for gemcitabine HCl market players.
Over a third of generic injectable products for cancer treatment are going off-patent by 2020, and the trend is likely to grow over the forecast period. Furthermore, Fact.MR finds that, the value creation of generic drugs will be around thrice that of the branded drugs.
Know More Details About the Report
North America in Vanguard, APAC to Emerge as Fast-Growing Market
Capturing around 40% of total gemcitabine HCl market stack, North America continues to engage shareholders over the time ahead.
Being a hotbed for innovations in the healthcare sector, favorable reimbursement policies and notable resource allocation to improve healthcare infrastructure are key factors shaping market in the developed region.
Manufacturers are also turning their sights to Asia Pacific (APAC), where the gemcitabine HCl market is expected to flourish at a noteworthy CAGR of over 7%.
In order to curb the expanding cancer patient pool, governments in countries – China, and India – are increasing their per capita healthcare spending.
Furthermore, this study reveals that, the usage of gemcitabine HCl in APAC is likely to surge to about 1.6x through 2027.
Market Players Emphasize on Reformulation Strategies to Maintain Competitiveness
R&D projects in the gemcitabine HCl drug market in the recent past have been primarily focusing on advancements in treatment delivery and combination therapy.
High unmet needs and limited efficacy of existing treatments in pancreatic cancer (mostly chemotherapies) have influenced market incumbents to explore better versions of branded gemcitabine agents.
For instance, NuCana Biomed’s Acelarin (NUC-1031), a reformulation of gemcitabine, is in late-stage clinical trials and has been engineered to overcome resistance mechanisms associated with the original drug.
Sun Pharma has launched ready-to-infuse INFUGEM (gemcitabine in sodium chloride injection) in the U.S. INFUGEM - the first chemotherapy product that comes in a premixed formulation.
The reformulation received approval by the U.S. Food and Drug Administration (FDA) in combination with other drugs for the treatment of breast, ovarian, non-small cell lung cancers, and as a single agent for the treatment of pancreatic cancer.
Avail customized purchase options for your needs
Gemcitabine HCl Market: In-Depth Analysis on Key Segments
Fact.MR has studied the gemcitabine HCl market with detailed segmentation on the basis of type, application, end users, and key regions.
“This taxonomy prepared is confidential and intended exclusively for the individual or entity with whom it is being shared. Reading, disseminating, distributing, or copying this to any party other than addressee(s) is unauthorized and prohibited.”
The Fact.MR study covers country-specific analysis on demand for gemcitabine HCl for each regional market in tandem with the market size valuation and projected price point analysis, price index, and impact of major regional and country-wise dynamics, which were gathered via quotes from several gemcitabine HCl manufacturers, experts, and suppliers.
The study also provides Y-o-Y growth projections on every regional market covered. Further, future trends, growth opportunities, and other factors associated with the market have been elaborated in the study.
The report offers company-level market share assessment, which has been deduced based on the company’s yearly sales and segmental revenue in every target end-use sectors.
The market has been projected on the basis of constant currency rates. The report also offer detailed competitive and company profiles of key participants running in the global gemcitabine HCl market.
Some of the major competitors operating in the robot process automation market are Eli Lilly and Company, Teva Pharmaceutical Industries Ltd., Accord-UK Ltd., Pfizer, Inc., Mylan N.V., Sun Pharmaceutical Industries Ltd., Fresenius Kabi AG, Dr. Reddy’s Laboratories Ltd., Ingenus Pharmaceuticals, and others.
Gemcitabine HCl Market - Scope Of The Report
The following study offers projection and assessment of the global gemcitabine HCl market along with the estimated data 2020 and forecast data up to 2027 in terms of value (US$ Mn) and volume (Kg), as per a Fact.MR report.
The report provides key trends that are currently impacting growth of the global gemcitabine HCl market along with numerous macro-economic indicators.
This recently published and insightful study on gemcitabine HCl puts emphasis on important dynamics, and their effect on the entire value chain from suppliers to end-users, which are likely to shape the future landscape of the global gemcitabine HCl market.
The Fact.MR study incorporates an in-depth analysis of recent industry trends and opportunities for gemcitabine HCl manufacturers. It also consists of value chain analysis including, the key market participants.
To facilitate users with a 360-degree view of the market, we have included a comprehensive competitive assessment about the leading players operating players in the market and strategic synopses.
The dashboard included in the report offers a thorough comparison of gemcitabine HCl producers on aspects - product offerings, total revenue, and key tactics.
Gemcitabine HCl Market: Research Methodology
Numerous primary and secondary sources were referred to during the course of the report. The latter include Morningstar, Factiva, and Hoovers, and company yearly reports and publications.
Comprehensive interviews have been organized by our analysts, and the intelligence and insights gathered have been utilized for authenticating the data collected via secondary research.
The study also contains an elaboration of assumptions and acronyms used for research purposes. Information collected has been authenticated with the help of the triangulation method to provide compelling quantitative and qualitative insights into the gemcitabine HCl market.
A brief market perspective covered in the study explains the macro-economic aspects that influence the growth of the gemcitabine HCl market including, global GDP growth rate, various sectors growth rate such as healthcare, pharmaceutical, and others.
This study serves as a genuine resource of intelligence on the gemcitabine HCl market, encouraging the readers to implement fact-based decisions on the future outlook of their businesses.
Need an Exclusive Report for your Unique Requirement?
- Our Clients -
- Evaluate How Fact.MR's Report Can Help. -
Is the market research conducted by Fact.MR?
Yes, the report has been compiled by expert analysts of Fact.MR, through a combination of primary and secondary research. To know more about how the research was conducted, you can speak to a research analyst.
What research methodology is followed by Fact.MR?
Fact.MR follows a methodology that encompasses the demand-side assessment of the market, and triangulates the same through a supply-side analysis. This methodology is based on the use of standard market structure, methods, and definitions.
What are the sources of secondary research?
Fact.MR conducts extensive secondary research through proprietary databases, paid databases, and information available in the public domain. We refer to industry associations, company press releases, annual reports, investor presentations, and research papers. More information about desk research is available upon request.
Who are the respondents for primary research?
Fact.MR speaks to stakeholders across the spectrum, including C-level executives, distributors, product manufacturers, and industry experts. For a full list of primary respondents, please reach out to us.
Is a sample of this report available for evaluation?
Yes, you can request a sample, and it will be sent to you through an email.